Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Bausch + Lomb Spotlights BL 1107 Eye Drop and ELIOS Implant-Free Laser as Glaucoma Catalysts

Summary by marketbeat.com
Bausch + Lomb (NYSE:BLCO) highlighted two glaucoma programs during a Wells Fargo-hosted “2026 MedTech Innovation Spotlight” call, focusing on BL 1107, a next-generation alpha-2 agonist eyedrop, and ELIOS, an implant-free excimer laser procedure designed to lower intraocular pressure (IOP) during cat

1 Articles

marketbeat.commarketbeat.com
Center

Bausch + Lomb Spotlights BL 1107 Eye Drop and ELIOS Implant-Free Laser as Glaucoma Catalysts

Bausch + Lomb (NYSE:BLCO) highlighted two glaucoma programs during a Wells Fargo-hosted “2026 MedTech Innovation Spotlight” call, focusing on BL 1107, a next-generation alpha-2 agonist eyedrop, and ELIOS, an implant-free excimer laser procedure designed to lower intraocular pressure (IOP) during cat

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Friday, March 27, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Rochester, New York icon

Rochester, New York

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal